Hematological Oncology

Papers
(The H4-Index of Hematological Oncology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA40
580 | CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF HIGH‐GRADE B‐CELL LYMPHOMAS TRANSFORMED FROM INDOLENT LYMPHOMAS IN HIV‐NEGATIVE AND HIV‐POSITIVE PATIENTS39
546 | PATIENT REPORTED OUTCOMES AND PREDICTORS OF INHIBITOR USE IN CHRONIC LYMPHOCYTIC LEUKEMIA—AN ANALYSIS OF THE LYMPHOMA COALITION’S 2024 GLOBAL PATIENT SURVEY38
522 | CLINICAL APPROACH AND OUTCOME OF DIFFUSE LARGE B CELL LYMPHOMA WITH PERSISTENT PET POSITIVITY AFTER FRONTLINE TREATMENT: SUBGROUP ANALYSIS OF THE STRIDER STUDY38
617 | INCIDENCE AND SURVIVAL OF MANTLE CELL LYMPHOMA IN ENGLAND 2014–2021: A NATIONAL COHORT STUDY FROM THE UNCOVER STUDY GROUP35
825 | MEASURING SYMPTOM IMPROVEMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: EMERGING RESULTS FROM AN INCLUSIVE, ITERATIVE PROCESS30
613 | LIMITED‐STAGE MANTLE CELL LYMPHOMA: CLINICAL FEATURES, MANAGEMENT, AND OUTCOMES IN A MULTICENTER RETROSPECTIVE STUDY FROM SPAIN27
161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM24
514 | CAN BASELINE 18F‐FDG PET/CT PREDICT THE PROGNOSIS OF PRIMARY CNS LYMPHOMA?23
801 | AS A NOVEL EPIGENETIC MODULATOR, EZH1/2 DUAL INHIBITOR HM97662 EXHIBITS ANTITUMOR EFFICACY IN HEMATOLOGICAL MALIGNANCIES AND OVERCOMES EZH2‐INHIBITOR MEDIATED RESISTANCE23
490 | MOLECULAR LANDSCAPE OF DISTINCT FOLLICULAR LYMPHOMA HISTOLOGIC GRADES: INSIGHTS FROM GENOMIC AND TRANSCRIPTOME ANALYSES22
439 | ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA22
361 | REAL‐WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE21
407 | RADIATION THERAPY FOR OLIGO‐RELAPSED/PROGRESSIVE DISEASE POST‐STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA: FACTORS ASSOCIATED WITH FAVORABLE OUTCOMES21
660 | IMPACT OF HEALTHCARE SETTING ON DIFFUSE LARGE B‐CELL LYMPHOMA OUTCOMES—A REAL‐WORLD COMPARATIVE STUDY21
20
639 | DIFFUSE LARGE B CELL LYMPHOMA: A TUNISIAN MULTICENTER EXPERIENCE20
372 | DECODING THE CD4+T CELL‐ HODGKIN REED‐STERNBERG CELL CROSSTALK: HOW TO CUT THE ACHILLES' HEEL OF PEDIATRIC HODGKIN LYMPHOMA?20
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S001619
295 | EARLY MORTALITY DLBCL PREDICTION WITH AN ENHANCED R‐IPI SCORE DEVELOPED USING AN ENSEMBLE MACHINE LEARNING MODEL19
19
290 | REAL‐WORLD SAFETY AND EFFICACY OF POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: ANALYSIS OF 500 PATIENTS IN THE POLASTAR STUDY19
0.20284700393677